Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 7.03
SNTA's Cash to Debt is ranked higher than
65% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. SNTA: 7.03 )
SNTA' s 10-Year Cash to Debt Range
Min: 2.39   Max: No Debt
Current: 7.03

F-Score: 3
Z-Score: -6.47
M-Score: -3.94
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -138.89
SNTA's ROE (%) is ranked higher than
52% of the 1318 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. SNTA: -138.89 )
SNTA' s 10-Year ROE (%) Range
Min: -2635.13   Max: -47.15
Current: -138.89

-2635.13
-47.15
ROA (%) -83.22
SNTA's ROA (%) is ranked higher than
54% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. SNTA: -83.22 )
SNTA' s 10-Year ROA (%) Range
Min: -2607.57   Max: 108.22
Current: -83.22

-2607.57
108.22
ROC (Joel Greenblatt) (%) -6576.14
SNTA's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 1405 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. SNTA: -6576.14 )
SNTA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6515.41   Max: 1600.97
Current: -6576.14

-6515.41
1600.97
Revenue Growth (3Y)(%) -100.00
SNTA's Revenue Growth (3Y)(%) is ranked higher than
53% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: 2.50 vs. SNTA: -100.00 )
SNTA' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 164.5
Current: -100

0
164.5
EBITDA Growth (3Y)(%) -3.00
SNTA's EBITDA Growth (3Y)(%) is ranked higher than
75% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. SNTA: -3.00 )
SNTA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -29.9   Max: 158.9
Current: -3

-29.9
158.9
EPS Growth (3Y)(%) -4.50
SNTA's EPS Growth (3Y)(%) is ranked higher than
77% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. SNTA: -4.50 )
SNTA' s 10-Year EPS Growth (3Y)(%) Range
Min: -37.2   Max: 166.5
Current: -4.5

-37.2
166.5
» SNTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SNTA Guru Trades in Q1 2014

John Burbank 46,620 sh (New)
Murray Stahl 11,000 sh (New)
Louis Moore Bacon Sold Out
Jim Simons Sold Out
» More
Q2 2014

SNTA Guru Trades in Q2 2014

Murray Stahl 11,000 sh (unchged)
John Burbank Sold Out
» More
Q3 2014

SNTA Guru Trades in Q3 2014

Jim Simons 377,275 sh (New)
Murray Stahl 11,000 sh (unchged)
» More
Q4 2014

SNTA Guru Trades in Q4 2014

Jim Simons 639,581 sh (+69.53%)
Murray Stahl 11,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with SNTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.70
SNTA's P/B is ranked higher than
73% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. SNTA: 4.70 )
SNTA' s 10-Year P/B Range
Min: 2.91   Max: 28.34
Current: 4.7

2.91
28.34
Current Ratio 3.22
SNTA's Current Ratio is ranked higher than
67% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. SNTA: 3.22 )
SNTA' s 10-Year Current Ratio Range
Min: 2.66   Max: 22.04
Current: 3.22

2.66
22.04
Quick Ratio 3.22
SNTA's Quick Ratio is ranked higher than
69% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. SNTA: 3.22 )
SNTA' s 10-Year Quick Ratio Range
Min: 2.66   Max: 22.04
Current: 3.22

2.66
22.04

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.10
SNTA's Price/Net Cash is ranked higher than
88% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 109.90 vs. SNTA: 5.10 )
SNTA' s 10-Year Price/Net Cash Range
Min: 4.65   Max: 18.68
Current: 5.1

4.65
18.68
Price/Net Current Asset Value 5.10
SNTA's Price/Net Current Asset Value is ranked higher than
87% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 45.70 vs. SNTA: 5.10 )
SNTA' s 10-Year Price/Net Current Asset Value Range
Min: 4.57   Max: 17.96
Current: 5.1

4.57
17.96
Price/Tangible Book 4.90
SNTA's Price/Tangible Book is ranked higher than
76% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. SNTA: 4.90 )
SNTA' s 10-Year Price/Tangible Book Range
Min: 3.07   Max: 30.05
Current: 4.9

3.07
30.05
Earnings Yield (Greenblatt) -51.80
SNTA's Earnings Yield (Greenblatt) is ranked lower than
67% of the 1393 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. SNTA: -51.80 )
SNTA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -57.6   Max: 1539.2
Current: -51.8

-57.6
1539.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:YDO.Germany,
Synta Pharmaceuticals Inc was incorporated in Delware in March 2000 and commenced operations in July 2001. The Company is a biopharmaceutical company, engaged in discovering, developing and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Its drug candidate, ganetespib, is a next generation Hsp90 inhibitor in Phase 3 development for non-small cell lung cancer (NSCLC) and in development program, including clinical trials for breast cancer, ovarian cancer and acute myeloid leukemia. In addition, It is developing a unique, proprietary platform for enhanced delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that it has developed. Its patent portfolio has a total of 906 patents and patent applications worldwide. With respect to its Hsp90 inhibitor program, it has 112 issued U.S. and foreign patents, and 154 pending U.S. and foreign counterpart patent applications.
» More Articles for SNTA

Headlines

Articles On GuruFocus.com
Insider Buys: FULL, FMI and SNTA Apr 10 2015 
Weekly 3-Year Low Highlights: NSR, ELRC, PLPC, SNTA Feb 16 2015 
5-year lows: Vivus, Synta Pharmaceuticals Inc, MVC Capital Inc, and Kemet Corp. Feb 09 2015 
5-year lows: Synta Pharmaceuticals Inc, Rex Energy Corp, Petroquest Energy Inc, and Liquidity Servic Jan 11 2015 
5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and Aeropostale I Dec 28 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI Jul 08 2012 
Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI Jul 07 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
Synta Pharmaceuticals Inc. (SNTA) CEO Safi R Bahcall buys 5,000 Shares Mar 15 2011 


More From Other Websites
A surge in interest in Synta's cancer drug ahead of key science data Apr 16 2015
Synta Pharmaceuticals (SNTA) Stock Rises Today After Announcing Upcoming Presentations Apr 16 2015
Synta Pharmaceuticals (SNTA) Catches Eye: Stock Jumps 10.7% - Tale of the Tape Apr 16 2015
Synta Announces Presentations at the 2015 Annual Meeting of the American Association of Cancer... Apr 16 2015
Synta Announces Presentations at the 2015 Annual Meeting of the American Association of Cancer... Apr 16 2015
SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 06 2015
Synta Pharmaceuticals Closes Public Offering of Common Stock Apr 06 2015
Synta Pharmaceuticals Closes Public Offering of Common Stock Apr 06 2015
SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Apr 01 2015
Synta Pharmaceuticals (SNTA) Stock Hits 52-Week Low After Pricing Public Offering Mar 31 2015
BUZZ-U.S. STOCKS ON THE MOVE-Lorillard, Charter Communications, Synta Pharma Mar 31 2015
Synta Pharmaceuticals Prices Public Offering of Common Stock Mar 31 2015
Synta Pharmaceuticals Prices Public Offering of Common Stock Mar 31 2015
BUZZ-U.S. STOCKS ON THE MOVE-Synta Pharma, Lorillard, BioCryst, Insmed Mar 31 2015
Synta Pharmaceuticals Announces Proposed Public Offering of Common Stock Mar 30 2015
Synta Pharmaceuticals Announces Proposed Public Offering of Common Stock Mar 30 2015
SYNTA PHARMACEUTICALS CORP Financials Mar 19 2015
Synta's Q4 Loss Narrows Y/Y, Focus on Lung Cancer Drug - Analyst Blog Mar 13 2015
Synta Pharmaceuticals Corp Earnings Call scheduled for 8:30 am ET today Mar 12 2015
Synta's (SNTA) Q4 Loss In Line with Expectations - Tale of the Tape Mar 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK